Please assess the completion status of the following clinical trial:

Trial Title: Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years old~* ST-segment elevation myocardial infarction~* Referred for primary PCI either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia~Exclusion Criteria:~* Unconsciousness~* Other conditions that make the patient incapable receiving integer loading dose of prasugrel~* Any contraindication and/or known hypersensitivity or allergy to aspirin, prasugrel, intravenous unfractionated heparin, cangrelor, tirofiban~* Any contraindication to primary PCI~* Administration of glycoprotein IIb/IIIa inhibitors (GPI) or P2Y12-inhibitors or cangrelor \< 7 days~* Chronic dialysis~* Recent (\< 15 days) or current major bleeding~* Recent (\< 15 days) major surgery~* Administration of fibrinolytics \< 30 days~* Current use or indication to oral anticoagulant~* Previous stroke or transient ischemic attack (TIA)~* Inability to follow the procedures of the study (language problems, psychological disorders, dementia) or comorbidities associated with less than 6 months survival (active malignancies drug or alcohol abuse, etc.)~* Women who are pregnant or breast feeding or with potential to become pregnant during the course of the study (age \< 55 years and last menstruation within the last 12 months) and did not undergo tubal ligation, ovariectomy or hysterectomy~* Participation in another study with investigational drug within the 30 days preceding and during the present study~* Enrolment of the investigator, his/her family members, employees and other dependent persons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cangrelor (Type: EXPERIMENTAL): Cangrelor bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI).
- Tirofiban (Type: ACTIVE_COMPARATOR): Tirofiban bolus of 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min).
- Prasugrel (Type: ACTIVE_COMPARATOR): Prasugrel oral integer or chewed at an identical loading dose of 60 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).